Copyright
©The Author(s) 2015.
World J Gastroenterol. May 28, 2015; 21(20): 6352-6360
Published online May 28, 2015. doi: 10.3748/wjg.v21.i20.6352
Published online May 28, 2015. doi: 10.3748/wjg.v21.i20.6352
Table 3 Summary of most common adverse events (occurring in 10% or more of patients in any group)
| Ref. | Group | General adverse events1 | |||||||||
| Ulcerative colitis aggravated | Nausea/vomiting | Headache | Frequent bowel movements | Fatigue | Upper respiratory tract infection | Abdominal pain/tenderness | Arthralgia | Dizziness | Rash | ||
| Feagan et al[14] | Intervention 1 | 29 (50) | 21 (36) | 12 (21) | 10 (17) | 8 (14) | 8 (14) | 10 (17) | 4 (7) | 6 (10) | 6 (10) |
| Intervention 2 | 22 (37) | 13 (22) | 11 (18) | 5 (8) | 5 (8) | 8 (13) | 6 (10) | 7 (12) | 4 (7) | 4 (7) | |
| Control | 24 (38) | 15 (24) | 13 (21) | 10 (16) | 7 (11) | 5 (8) | 16 (25) | 5 (8) | 1 (2) | 4 (6) | |
| Feagan et al[15] | Intervention | 97 (13) | 38 (5) | 80 (11) | NA | 33 (4) | 132 (18) | 50 (7) | 56 (8) | NA | NA |
| Control | 58 (39) | 19 (13) | 28 (19) | NA | 10 (7) | 47 (32) | 10 (7) | 25 (17) | NA | NA | |
| Parikh et al[16] | Intervention 1 | 2 (17) | NA | 2 (17) | NA | NA | 4 (33) | NA | NA | 1 (8) | NA |
| Intervention 2 | 1 (7) | NA | 3 (21) | NA | NA | 3 (21) | NA | NA | 0 (0) | NA | |
| Intervention 3 | 0 (0) | NA | 2 (18) | NA | NA | 1 (9) | NA | NA | 0 (0) | NA | |
| Control | 4 (44) | NA | 1 (11) | NA | NA | 4 (44) | NA | NA | 1 (11) | NA | |
| Feagan et al[14] | Intervention 1 | 6 (10) | NA | NA | NA | NA | NA | NA | 6 (10) | 18 (15)2 | |
| Intervention 2 | 3 (5) | NA | NA | NA | NA | NA | NA | 12 (20) | |||
| Control | 8 (13) | NA | NA | NA | NA | NA | NA | 6 (10) | |||
| Feagan et al[15] | Intervention | NA | 35 (5) | 13 (2) | NA | NA | NA | NA | 77 (10) | ||
| Control | NA | 16 (11) | 36 (24) | NA | NA | NA | NA | 37 (25) | |||
| Parikh et al[16] | Intervention 1 | NA | NA | 0 (0) | 0 (0) | 0 (0) | 1 (8) | 0 (0) | 1 (8) | 2 (5)2 | |
| Intervention 2 | NA | NA | 2 (14) | 2 (14) | 2 (14) | 0 (0) | 0 (0) | 0 (0) | |||
| Intervention 3 | NA | NA | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (9) | 1 (9) | |||
| Control | NA | NA | 0 (0) | 0 (0) | 0 (0) | 1 (11) | 1 (11) | 0 (0) | |||
- Citation: Jin Y, Lin Y, Lin LJ, Zheng CQ. Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis. World J Gastroenterol 2015; 21(20): 6352-6360
- URL: https://www.wjgnet.com/1007-9327/full/v21/i20/6352.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i20.6352